Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks

RegulatoryapprovedVyeptiPositive

AI Analysis

Summary

Lundbeck received marketing authorization from Japan's MHLW for Vyepti (eptinezumab), an intravenous CGRP-targeted preventive treatment for migraine attacks in adults, expanding its global presence to over 30 countries.

Outcome Details

Marketing authorization granted by Japan's MHLW for Vyepti (eptinezumab) for the prevention of migraine attacks in adults

Importance:7/10

Sentiment:

0.85

migraine preventionCGRP inhibitorJapan approvalintravenous treatmentregulatory approval

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Pharma on September 16, 2026 6:22 AM

Read Original